Barclays’s Prime Medicine PRME Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $284K | Buy |
114,802
+43,378
| +61% | +$107K | ﹤0.01% | 3338 |
|
|
2025
Q1 | $143K | Sell |
71,424
-26,197
| -27% | -$52.5K | ﹤0.01% | 3532 |
|
|
2024
Q4 | $285K | Buy |
97,621
+12,924
| +15% | +$37.7K | ﹤0.01% | 3350 |
|
|
2024
Q3 | $328K | Buy |
84,697
+65,593
| +343% | +$254K | ﹤0.01% | 3232 |
|
|
2024
Q2 | $98K | Sell |
19,104
-8,486
| -31% | -$43.5K | ﹤0.01% | 3389 |
|
|
2024
Q1 | $193K | Sell |
27,590
-26,645
| -49% | -$186K | ﹤0.01% | 3354 |
|
|
2023
Q4 | $480K | Sell |
54,235
-10,905
| -17% | -$96.5K | ﹤0.01% | 3022 |
|
|
2023
Q3 | $621K | Buy |
65,140
+57,261
| +727% | +$546K | ﹤0.01% | 2414 |
|
|
2023
Q2 | $116K | Buy |
7,879
+2,543
| +48% | +$37.4K | ﹤0.01% | 3339 |
|
|
2023
Q1 | $65K | Buy |
5,336
+2,549
| +91% | +$31.1K | ﹤0.01% | 3705 |
|
|
2022
Q4 | $52K | Buy |
+2,787
| New | +$52K | ﹤0.01% | 3765 |
|